PVLA NASDAQ
Palvella Therapeutics, Inc.
1W: -4.1%
1M: -13.4%
3M: -5.6%
YTD: +32.1%
1Y: +109.5%
$132.47
-0.26 (-0.20%)
Weekly Expected Move ±5.3%
$119
$126
$132
$139
$146
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (100)
U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
3,600 Shares in Palvella Therapeutics, Inc. $PVLA Acquired by Jupiter Topco LLC
Bank of New York Mellon Corp Invests $4.67 Million in Palvella Therapeutics, Inc. $PVLA
Bank of America Corp DE Has $4.73 Million Holdings in Palvella Therapeutics, Inc. $PVLA
Palvella (PVLA) Q2 2026 Earnings Call Transcript
Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Arete Wealth Advisors LLC Makes New $2.18 Million Investment in Palvella Therapeutics, Inc. $PVLA
Fifth Third Bancorp Invests $2.49 Million in Palvella Therapeutics, Inc. $PVLA
$PVLA stock is down 10% today. Here's what we see in our data. - Quiver Quantitative
Palvella Therapeutics (PVLA) Sees Significant Decline - GuruFocus
Palvella Therapeutics (PVLA) Sees Significant Decline - GuruFocus
Palvella Therapeutics (PVLA) COO exercises options, then sells 4,302 shares - Stock Titan
Palvella Therapeutics (PVLA) Submits Initial Module of NDA For QTORIN - Yahoo Finance
Palvella Therapeutics (PVLA) Submits Initial Module of NDA For QTORIN
How Pieris Pharmaceuticals Inc. (PVLA) Affects Rotational Strategy Timing - Stock Traders Daily
Palvella Therapeutics (PVLA) Proxy filing Summary - Quartr
(PVLA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally
What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally
CCORF Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $227 - Moomoo
6 Biotech Stocks That Delivered Stunning Gains: INBX +700%, PVLA +500%, MBX +300%, ABSI +200% & More - RTTNews
Palvella Shares Advance After FDA Grants Rolling Review for Rare Disease Therapy
FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations
Palvella Shares Advance After FDA Grants Rolling Review for Rare Disease Therapy - Yahoo Finance
Palvella Therapeutics (PVLA) Stock Valuation Check After Strong Recent Momentum
Palvella Therapeutics (PVLA) Stock Valuation Check After Strong Recent Momentum - Yahoo Finance
Assessing Palvella Therapeutics (PVLA) Valuation After A Strong 1-Year Run And Recent Share Price Pullback - simplywall.st
Palvella Therapeutics: Qtorin Continues Making Progress, So I Remain Bullish - Seeking Alpha
Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
The Prognosis For Palvella Therapeutics (NASDAQ:PVLA) - Seeking Alpha
$PVLA stock is up 8% today. Here's what we see in our data. - Quiver Quantitative
Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards
Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malformations
Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malformations
Palvella’s QTORIN Trial Data Reframes Venous Malformation Outlook And Valuation
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
Palvella Therapeutics approved for transfer to Nasdaq Global Market
Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market
LGND: 1Q:26 Results Highlight Breadth of Portfolio
Palvella Therapeutics Q1 Earnings Call Highlights
Ligand Pharmaceuticals Q1 Earnings Call Highlights
Palvella targets 2H 2026 NDA filing while outlining >$1B peak U.S. sales potential for QTORIN rapamycin in microcystic lymphatic malformations
Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Ligand to Participate in May Investor Conferences
Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas
Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026
Deltec Asset Management LLC Has $251,000 Stock Position in Palvella Therapeutics, Inc. $PVLA
New Palvella Director Brings Rare Disease Insight To Low Valued Stock - Yahoo Finance
Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026
Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
Analysts Set Palvella Therapeutics, Inc. (NASDAQ:PVLA) Price Target at $198.07
Equities Analysts Offer Predictions for PVLA FY2026 Earnings
What is HC Wainwright’s Forecast for PVLA FY2026 Earnings?
Q1 Earnings Forecast for PVLA Issued By HC Wainwright
Palvella Therapeutics GAAP EPS of -$3.71 misses by $0.19
Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
Earnings Scheduled For March 31, 2026
$PVLA stock is up 11% today. Here's what we see in our data. - Quiver Quantitative
Quant snapshot: J. Jill, AngioDynamics leads strong buys as INmune Bio, Terrestrial Energy lag
Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting
Palvella Stock Up 340% as Insider Sells Shares. Here's What the Move Does (And Does Not) Signal
Director Buys $500,000 Worth of Palvella Therapeutics Shares After Phase 3 Win
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
Kathleen Goin Sells 4,302 Shares of Palvella Therapeutics (NASDAQ:PVLA) Stock
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin
Apis Capital Advisors LLC Makes New Investment in Palvella Therapeutics, Inc. $PVLA
Analysts Set Palvella Therapeutics, Inc. (NASDAQ:PVLA) Price Target at $184.87
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
Palvella Therapeutics Closes $230 Million Upsized Public Offering of Common Stock - Quiver Quantitative
Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up Following Analyst Upgrade
Palvella Therapeutics stock rises on $200M share offering
Palvella Therapeutics Announces Pricing of Upsized Public Offering
Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright - Yahoo Finance
Palvella Therapeutics launches $150M public stock offering
Palvella surges on late-stage trial win for lead asset
Palvella Therapeutics Announces Proposed Public Offering
Palvella plans $150M stock sale for rare skin therapy research - Stock Titan
Palvella (PVLA) Stock Pre-Market (+13%): Phase 3 Topline Data Anticipation - Trefis
PVLA Stock Soars On Strong Phase 3 Results For Rare Vascular Disorder Treatment - Stocktwits
Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
Analysts Set Palvella Therapeutics, Inc. (NASDAQ:PVLA) Price Target at $158.69
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives $158.69 Consensus Price Target from Analysts
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Short Interest Up 60.9% in December
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies
Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs